Log In Sign up
The largest database of trusted experimental protocols

Angptl7

Manufactured by R&D Systems
Visit Supplier

ANGPTL7 is a member of the angiopoietin-like protein family. It is a secreted glycoprotein that plays a role in angiogenesis and lipid metabolism. ANGPTL7 is expressed in various tissues, including the eye, kidney, and liver.

Automatically generated - may contain errors

Lab products found in correlation

Pdgf d, by R&D Systems (2 mentions) Igf 1, by Thermo Fisher Scientific (2 mentions) Igfbp3 elisa, by RayBiotech (2 mentions) Igfbp3, by ProSpec (2 mentions) Epidermal growth factor (egf), by Thermo Fisher Scientific (2 mentions)

2 protocols using angptl7

1

Modulation of Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols
Identifiers for shRNAs used in this study are: V3LHS-644610 (shFRA1#1), V3LHS-644611 (shFRA1#2), V3LHS-320021 (shIGFBP3#1), V2LHS-111629 (shIGFBP3#2) (Dharmacon, GE Lifesciences). IGFBP3 ELISA (Raybiotech) was performed according to the manufacturer’s instructions with 50ug tumour lysate and conditioned media was diluted 1:5. Recombinant proteins were used at the following conditions: 10ng/ml IGF1 (Invitrogen), 10ng/ml EGF (Invitrogen), 10ng/ml PDGFD (R&D Systems), 2μg/ml IGFBP3 (Prospec) for 15min, or 5ug/ml ANGPTL7 (R&D Systems) for 30min.
Obenauf A.C., Zou Y., Ji A.L., Vanharanta S., Shu W., Shi H., Kong X., Bosenberg M.C., Wiesner T., Rosen N., Lo R.S, & Massagué J. (2015). Therapy-induced tumour secretomes promote resistance and tumour progression. Nature, 520(7547), 368-372.
+ Open protocol
+ Expand
2

Modulation of Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols
Identifiers for shRNAs used in this study are: V3LHS-644610 (shFRA1#1), V3LHS-644611 (shFRA1#2), V3LHS-320021 (shIGFBP3#1), V2LHS-111629 (shIGFBP3#2) (Dharmacon, GE Lifesciences). IGFBP3 ELISA (Raybiotech) was performed according to the manufacturer’s instructions with 50ug tumour lysate and conditioned media was diluted 1:5. Recombinant proteins were used at the following conditions: 10ng/ml IGF1 (Invitrogen), 10ng/ml EGF (Invitrogen), 10ng/ml PDGFD (R&D Systems), 2μg/ml IGFBP3 (Prospec) for 15min, or 5ug/ml ANGPTL7 (R&D Systems) for 30min.
Obenauf A.C., Zou Y., Ji A.L., Vanharanta S., Shu W., Shi H., Kong X., Bosenberg M.C., Wiesner T., Rosen N., Lo R.S, & Massagué J. (2015). Therapy-induced tumour secretomes promote resistance and tumour progression. Nature, 520(7547), 368-372.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!